| Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity A Casazza, D Laoui, M Wenes, S Rizzolio, N Bassani, M Mambretti, ... Cancer cell 24 (6), 695-709, 2013 | 632 | 2013 |
| Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis Y Takeda, S Costa, E Delamarre, C Roncal, R Leite de Oliveira, ... Nature 479 (7371), 122-126, 2011 | 317 | 2011 |
| Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment A Casazza, G Di Conza, M Wenes, V Finisguerra, S Deschoemaeker, ... Oncogene 33 (14), 1743-1754, 2014 | 274 | 2014 |
| Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity RL de Oliveira, S Deschoemaeker, AT Henze, K Debackere, ... Cancer cell 22 (2), 263-277, 2012 | 135 | 2012 |
| The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1α levels and colorectal cancer cell survival under hypoxia G Di Conza, ST Cafarello, S Loroch, D Mennerich, S Deschoemaeker, ... Cell reports 18 (7), 1699-1712, 2017 | 110 | 2017 |
| Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization S Tugues, S Honjo, C König, O Noguer, M Hedlund, J Botling, ... Cancer research 72 (8), 1953-1963, 2012 | 57 | 2012 |
| PHD 1 regulates p53‐mediated colorectal cancer chemoresistance S Deschoemaeker, G Di Conza, S Lilla, R Martín‐Pérez, D Mennerich, ... EMBO Molecular Medicine 7 (10), 1350-1365, 2015 | 53 | 2015 |
| Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions E Verheye, J Bravo Melgar, S Deschoemaeker, G Raes, A Maes, ... International Journal of Molecular Sciences 23 (2), 904, 2022 | 37 | 2022 |
| Selectively Targeting Tumor Hypoxia with the Hypoxia-Activated Prodrug CP-506 AMA van der Wiel, V Jackson-Patel, R Niemans, A Yaromina, E Liu, ... Molecular Cancer Therapeutics 20 (12), 2372-2383, 2021 | 27 | 2021 |
| Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages A Murgaski, M Kiss, H Van Damme, D Kancheva, I Vanmeerbeek, ... Cancer Research 82 (20), 3785-3801, 2022 | 16 | 2022 |
| Dendritic cell vaccines: A promising approach in the fight against ovarian cancer AA Caro, S Deschoemaeker, L Allonsius, A Coosemans, D Laoui Cancers 14 (16), 4037, 2022 | 15 | 2022 |
| In vivo identification of adducts from the new hypoxia-activated prodrug CP-506 using DNA adductomics MJ Solivio, A Stornetta, J Gilissen, PW Villalta, S Deschoemaeker, ... Chemical research in toxicology 35 (2), 275-282, 2022 | 13 | 2022 |
| Impact of myo‐inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models LBA Tran, TT Cao‐Pham, BF Jordan, S Deschoemaeker, A Heyerick, ... Journal of cellular and molecular medicine 23 (3), 1908-1916, 2019 | 12 | 2019 |
| Heterogeneity and function of macrophages in the breast during homeostasis and cancer E Hadadi, S Deschoemaeker, GV Venegas, D Laoui International Review of Cell and Molecular Biology 367, 149-182, 2022 | 4 | 2022 |
| CP-506, a next generation hypoxia-activated prodrug, as promising novel anti-cancer therapeutic S Thiolloy, S Deschoemaeker, N Ongenae, J Gilissen, L Dubois, ... Cancer Research 78 (13_Supplement), 4959-4959, 2018 | 3 | 2018 |
| Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models EJ Clappaert, D Kancheva, J Brughmans, A Debraekeleer, PMR Bardet, ... Frontiers in Immunology 14, 1166180, 2023 | 2 | 2023 |
| Prodrugs and medical uses thereof A Heyerick, S DESCHOEMAEKER, S THIOLLOY, D TERSAGO, P Lambin | 1 | 2019 |
| EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug R Niemans, A Yaromina, J Theys, D Marcus, A Ashoorzadeh, M Abbattista, ... | 1 | 2018 |
| CCR8 as novel target for tumor-infiltrating Tregs in triple negative breast cancer S Deschoemaeker Recent insights into Immuno-Oncology, 2022 | | 2022 |
| Distinct cDC subsets co-operate in CD40 agonist response while suppressive microenvironments and lack of antigens subvert efficacy A Murgaski, M Kiss, H Van Damme, D Kancheva, I Vanmeerbeek, ... bioRxiv, 2021.12. 25.474021, 2021 | | 2021 |
